SC Pharmaceuticals(SZ:002693) Mei Ri Jing Ji Xin Wen·2025-12-18 08:32Core Viewpoint - The approval of the abbreviated new drug application (ANDA) for injectable bortezomib by the U.S. FDA marks a significant milestone for the company, indicating that its product meets the safety and efficacy standards of the original research level, which is expected to enhance the company's international influence and future operating performance [2]. Group 1 - The company received notification from the U.S. FDA regarding the approval of its ANDA for injectable bortezomib [2]. - The approval signifies that the company's research and production of injectable bortezomib have reached the original research level in terms of safety and efficacy [2]. - This development is anticipated to have a positive impact on the company's international product influence and future business performance [2].